Stanley-Laman Group’s Medpace MEDP Stock Holding History

Stanley-Laman Group’s Portfolio MEDP Stock Details MEDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,241	Closed	-$270K	–	295
2021 Q4	$270K	Buy	+1,241	New	+$260K	0.03%	245

Other funds holding MEDP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ESCM

Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VVP

Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stanley-Laman Group's MEDP Position: Q1 2022 in Review

Stanley-Laman Group sold out of Medpace (MEDP) in Q1 2022, closing a stake of 1,241 shares — an estimated $270K sold.

Stanley-Laman Group first reported a position in MEDP in Q4 2021 and held it in 1 quarter. The position peaked at $270K in Q4 2021. 349 funds tracked by Wall St. Rank hold MEDP as of Q1 2022.

Stanley-Laman Group reported no remaining Medpace position as of Q1 2022 after selling out during the quarter.
Stanley-Laman Group sold 1,241 Medpace shares in Q1 2022, an estimated $270K.
Stanley-Laman Group first reported a position in Medpace in Q4 2021 and held it in 1 quarter.
Stanley-Laman Group's Medpace position peaked at $270K in Q4 2021.
349 funds tracked by Wall St. Rank held Medpace as of Q1 2022.

Based on Stanley-Laman Group's 13F filing for Q1 2022, filed 21 Apr 2022.